At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Physiologic Effects of Long-Term GHRH1-44 in Abdominal Obesity
In Brief
A Phase 2 clinical trial evaluating Growth hormone releasing hormone (GHRH) 1-44 and Placebo for Abdominal Obesity and Growth Hormone Deficiency. Completed, enrolled 60 participants across 1 site.
Detailed Summary
Obesity, a condition that occurs when a person has too much body fat, affects about 31% of people in the United States. It is associated with increased risk of diabetes, high blood pressure, high cholesterol, and cardiovascular disease. Abdominal obesity, in particular, is also associated with low levels of growth hormone, a hormone that affects rate of growth and the way the body uses energy. Growth hormone releasing hormone (GHRH) is a substance that makes the body naturally increase its own growth hormone levels. Administering GHRH to people who are obese may help return their growth hormone levels to normal and, in turn, may lead to reduced abdominal fat and improved cardiovascular function. This study will evaluate the effectiveness of synthetic GHRH in decreasing the amount of abdominal fat and improving cardiovascular function in people who are obese.
Study Details
Timeline
Interventions
2-mg sub-cutaneous injections once daily for 12 months
2-mg sub-cutaneous injections once daily for 12 months